Market cap
$277 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.6
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -- | -- | -- |
| Net Profit | 40.15 | 75.87 | 50.09 | 15.34 | 4.60 |
| EPS | 39.35 | 77.48 | 52.32 | 16.70 | 7.47 |
| Book Value | -- | -- | -22.85 | -15.84 | 21.13 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Sep-25 | Sep-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -1,428.89 | -- | -- | -- |
| Return on equity
| -36.44 | -36.93 | -20.11 | -43.11 | -32.81 |
| Return on Capital
| -36.44 | -36.93 | -- | -43.11 | -32.81 |
| Return on Assets
| -33.11 | -33.70 | -13.62 | -38.75 | -29.66 |
| Debt to Equity (x)
| -- | -- | 0.00 | -- | -- |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
-43.11
|
-32.81
|
-33.40
|
-32.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-20.11
Higher than Peers by 20.29
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
-20.11
|
-43.11
|
-32.81
|
-33.40
|
-32.71
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-13.62
Higher than Peers by 17.35
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
-13.62
|
-38.75
|
-29.66
|
-30.93
|
-30.53
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-83.62
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
--
|
-1,983.05
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
53.95
|
--
|
--
|
--
|
--
|
EBIT Growth
--
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
4.64
|
0.25
|
36.36
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
50.09
Higher than Peers by 57.39
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
50.09
|
-7.85
|
9.45
|
1.02
|
-26.56
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
52.32
Higher than Peers by 37.67
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
52.32
|
-0.05
|
0.14
|
0.05
|
-0.25
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
15.42
Higher than Peers by 25.59
Year on year growth in book value per share
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
15.42
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
15.62
Higher than Peers by 9.81
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
15.62
|
11.60
|
8.86
|
12.32
|
14.95
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
15.62
Higher than Peers by 9.92
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
15.62
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
-49.27
|
-50.28
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
19.14
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
-16.48
|
-11.10
|
-11.00
|
-16.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
2.58
Lower than Peers by 2.60
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
2.58
|
8.06
|
3.97
|
3.68
|
5.57
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-5.54
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
-5.54
|
-14.27
|
-8.02
|
-7.82
|
-13.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
277
Higher than Peers by 131
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Sep-25
|
Sep-24
|
Sep-23
|
Sep-22
|
|---|---|---|---|---|---|
|
Anavex Life Sciences (AVXL)
|
277
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|